We support pharmaceutical, biotech and medtech organisations to translate innovation into sustainable commercial outcomes, aligning evidence, pricing and market access strategy across the product lifecycle. Our advice is grounded in health economics, HTA and policy realities, ensuring commercial strategies are credible, defensible and executable.

Decision Context

Commercialisation decisions shape not only market success, but also the evidence, pricing and access options available over time. Choices around indication prioritisation, sequencing, pricing ambition and launch timing directly influence reimbursement outcomes, payer acceptance and long-term value.

These decisions are often made under uncertainty balancing clinical promise, evidence maturity, investor expectations and policy constraints and require an integrated, evidence-led approach.

---

Our Role

Pulse Economics works with early-stage innovators and established organisations to design commercialisation and growth strategies that are tightly aligned to reimbursement and funding realities.

We help clients clarify strategic options, evaluate trade-offs and prioritise pathways that are commercially attractive and HTA-credible, drawing on our deep understanding of how value is assessed by payers, policymakers and investors.

---

What We Deliver in Practice

Our commercialisation and growth strategy support includes:

Market & Indication Strategy

• Indication prioritisation and sequencing
• Market attractiveness and competitive landscape assessment
• Alignment of clinical development and commercial objectives

Value Proposition & Positioning

• Evidence-led value proposition development
• Differentiation and positioning relative to standard of care
• Integration of clinical, economic and policy value narratives

Pricing & Launch Strategy

• Pricing ambition and scenario analysis informed by HTA and payer expectations
• Launch sequencing and market entry strategy
• Alignment of pricing strategy with reimbursement and funding pathways

Lifecycle & Growth Planning

• Lifecycle management and expansion strategy
• Identification of follow-on indications or segments
• Strategy to support post-launch evidence generation and value reinforcement

---

Our Approach

Our approach to commercialisation and growth strategy is:

• Evidence-led — grounded in clinical, economic and outcomes evidence
• HTA-aware — aligned to reimbursement, payer and policy decision frameworks
• Integrated — linking R&D, modelling, pricing and market access strategy
• Pragmatic — recognising uncertainty, resource constraints and real-world trade-offs

We focus on developing strategies that are commercially compelling and decision-credible, rather than aspirational but misaligned with funding realities.

---

Managing Uncertainty & Trade-Offs

Commercial growth is rarely linear. We help clients navigate uncertainty by:

• Exploring alternative strategic scenarios
• Stress-testing pricing and access assumptions
• Identifying risks to uptake, reimbursement and sustainability
• Designing strategies that remain robust as evidence and policy evolve

This ensures commercial plans are resilient, adaptable and defensible.

---

Where This Service Applies

This service supports decisions across:

• Early-stage feasibility and commercial potential assessment
• Pre-launch strategy and evidence positioning
• Launch and market entry planning
• Post-launch growth and lifecycle management

Our advice is tailored to product maturity, organisational context and strategic objectives.

---

Why Pulse Economics

• Deep understanding of how evidence, pricing and access shape commercial outcomes
• Strong integration across R&D, modelling, market access and policy advisory
• HTA- and payer-informed commercial strategy
• Independent, evidence-based advice grounded in real decision environments

---

---

---